Latest Breaking News On - Niklas worm andersson - Page 1 : comparemela.com

Thiazide Diuretics May Promote Hyponatremia

The risk for hyponatremia was higher with thiazide drugs compared with nonthiazide drugs in older adults and patients with comorbidities.

Niklas worm anderssonStatens serum institutMedscape medicalInternal medicineData reinforce needNoel deepAspirus langlade hospitalHyponatremia hyponatraemiaAdverse effectsSide effectsElder careGeriatric medicineOlder adultsSenior citizensPatient safetyCalcium channel blockers

Treatment initiation with thiazide diuretics increases hyponatremia risk, researchers find

Treatment initiation with thiazide diuretics increases hyponatremia risk, researchers find
medicalxpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicalxpress.com Daily Mail and Mail on Sunday newspapers.

Worm anderssonStatens serum institutNiklas worm anderssonCumulative incidenceThiazide induced hyponatremiaInternal medicine

LDL-Lowering Tied to Lower First CVD Events in Patients 70+

People 70 years of age and older taking LDL cholesterol-lowering therapy for primary prevention have the same reduction in major vascular events as their younger counterparts, new research confirms.

Safiu khanNovo nordiskVascular centerDepartment of epidemiology researchJournal of the american college cardiologyHouston methodist debakey heartNiklas worm anderssonEpidemiology researchStatens serum institutAmerican collegeTine lovsIpid managementLow ldl cholesterolOw low density lipoprotein cholesterolAtherosclerotic heart diseaseTherosclerotic cardiovascular disease

Comparative effectiveness of bivalent BA 4-5 and BA 1 mRNA booster vaccines among adults aged ≥50 years in Nordic countries: nationwide cohort study

Objective To estimate the effectiveness of the bivalent mRNA booster vaccines containing the original SARS-CoV-2 and omicron BA.4-5 or BA.1 subvariants as the fourth dose against severe covid-19. Design Nationwide cohort analyses, using target trial emulation. Setting Denmark, Finland, Norway, and Sweden, from 1 July 2022 to 10 April 2023. Participants People aged ≥50 years who had received at least three doses of covid-19 vaccine (that is, a primary course and a first booster). Main outcome measures The Kaplan-Meier estimator was used to compare the risk of hospital admission and death related to covid-19 in people who received a bivalent Comirnaty (Pfizer-BioNTech) or Spikevax (Moderna) BA.4-5 or BA.1 mRNA booster vaccine as a fourth dose (second booster) with three dose (first booster) vaccinated people and between four dose vaccinated people. Results A total of 1 634 199 people receiving bivalent BA.4-5 fourth dose booster and 1 042 124 receiving bivalent BA.1 fourth

United kingdomNorth carolinaUnited statesNicklas pihlstrUlrike baumHinta meijerinkEmilia myrup thiessonRickard ljungJostein starrfeltSpikevax modernaEero poukkaAnders hviidEuropean medicines agencyFinnish medical foundationSanofi aventisNiklas worm andersson

Safety of BA 4-5 or BA 1 bivalent mRNA booster vaccines: nationwide cohort study

Objective To examine the association between the omicron adapted bivalent mRNA covid-19 booster vaccines received as a fourth dose and risk of adverse events. Design Nationwide cohort study. Setting Denmark. Participants 2 225 567 adults aged ≥50 years who received three covid-19 vaccine doses during the study period, 1 January 2021 to 10 December 2022. Main outcome measures The main outcome measure was rates of hospital visits for 27 different adverse events in a 28 day main risk period after vaccination with a bivalent omicron adapted mRNA booster vaccine as a fourth dose compared with reference period rates from day 29 after the third or fourth vaccine dose and onward. Results 1 740 417 adults (mean age 67.8 years, standard deviation 10.7 years) received a bivalent mRNA vaccine as a fourth dose. Fourth dose vaccination with a bivalent mRNA vaccine was not associated with a statistically significant increased rate of any of the 27 adverse outcomes within 28 days (eg, i

Anders hviidEmilia myrup thiessonDrug administrationCenters for diseaseUs centers for diseaseDanish ministry of healthDanish healthNiklas worm anderssonMyrup thiessonDisease controlVaccine adverse event reporting systemSafety datalinkStatens serum institutDanish ministryOpen accessCreative commons attribution non commercial